Update shared on04 Oct 2025
Fair value Decreased 70%Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples.
What's in the News
- Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
- The company signed a strategic Memorandum of Understanding with a regional manufacturing and distribution partner in Saudi Arabia to explore a joint venture in the Middle East and North Africa region for its PCR platform products.
- In silico analysis confirmed the primers used in Co-Primers-based PCR tests show high effectiveness for detecting chikungunya virus, with global health implications for areas at risk of mosquito-borne diseases.
- Co-Diagnostics completed its share buyback program, repurchasing 4,848,678 shares, representing 14.76% of shares for $15.58 million, with no shares repurchased in the latest quarter.
Valuation Changes
- Fair Value Estimate: Declined sharply from $10.00 to $3.00. This reflects a significant reduction in perceived company value.
- Discount Rate: Slightly decreased from 7.77% to 7.59%, indicating marginally lower risk expectations.
- Revenue Growth Forecast: Remained stable at approximately 399.22%, showing no change in growth outlook.
- Net Profit Margin: Essentially unchanged, moving from 31.73% to 31.73%.
- Future P/E Ratio: Dropped considerably from 14.85x to 4.43x, suggesting lower expectations for future earnings multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.